The OCTAVE Study
The OCTAVE clinical study (ColoAd1-2001) is a phase I/II non-randomised multicentre study of enadenotucirev administered either intraperitoneally (IP) or intravenously (IV) to patients with platinum-resistant epithelial ovarian cancer, either alone or in combination with paclitaxel administered weekly intravenously.
The ongoing phase II part of the study aims to determine whether IV enadenotucirev in combination with IV paclitaxel has a risk benefit profile that supports further investigation in the treatment of patients with platinum-resistant epithelial ovarian cancer.
This trial is currently recruiting subjects in the UK and Spain.
For more information about this trial and the participating centres, please follow these links:
Poster Presented at ASCO 2016